内分泌科医生参与临床护理团队与冠状动脉旁路移植术后2型糖尿病患者钠-葡萄糖协同转运蛋白2抑制剂处方的关联：一项双中心研究
Association of Endocrinologists on Clinical Care Team With Sodium-Glucose Cotransporter 2 Inhibitor Prescription for People With Type 2 Diabetes After Coronary Artery Bypass Grafting: A Two-Center Study.
作者信息
Yi Yangtian, Kumar Nicolas, Smith Matthew R, Mueller Ariel, Houle Timothy, Jassar Arminder, Cornella Lauren J, Schonberger Robert B, Bardia Amit
机构信息
Deparment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
出版信息
Clin Diabetes. 2025 Mar 6;43(3):409-415. doi: 10.2337/cd24-0107. eCollection 2025 Summer.
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are underutilized in people with type 2 diabetes after coronary artery bypass grafting (CABG). This study investigated the association of the presence of an endocrinologist on treatment teams with SGLT2 inhibitor prescription in patients with type 2 diabetes after CABG. The presence of an endocrinologist was associated with a more than twofold increase in the odds of obtaining an SGLT2 inhibitor prescription. This finding suggests that involving endocrinologists in these patients' postoperative care may improve prescription and use of SGLT2 inhibitors after CABG.
摘要
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂在冠状动脉旁路移植术（CABG）后的2型糖尿病患者中未得到充分利用。本研究调查了内分泌科医生参与治疗团队与CABG术后2型糖尿病患者使用SGLT2抑制剂处方之间的关联。内分泌科医生的参与使开具SGLT2抑制剂处方的几率增加了两倍多。这一发现表明，让内分泌科医生参与这些患者的术后护理可能会改善CABG后SGLT2抑制剂的处方开具和使用情况。
相似文献
1
Association of Endocrinologists on Clinical Care Team With Sodium-Glucose Cotransporter 2 Inhibitor Prescription for People With Type 2 Diabetes After Coronary Artery Bypass Grafting: A Two-Center Study.内分泌科医生参与临床护理团队与冠状动脉旁路移植术后2型糖尿病患者钠-葡萄糖协同转运蛋白2抑制剂处方的关联：一项双中心研究
Clin Diabetes. 2025 Mar 6;43(3):409-415. doi: 10.2337/cd24-0107. eCollection 2025 Summer.
2
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤：系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
3
Sodium-glucose cotransporter 2 inhibitors and inverse risk of new-onset atopic dermatitis in a cohort with diabetes: a nationwide active-comparator study.钠-葡萄糖协同转运蛋白2抑制剂与糖尿病队列中新发特应性皮炎的反向风险：一项全国性活性对照研究
Br J Dermatol. 2025 Jun 20;193(1):74-84. doi: 10.1093/bjd/ljaf086.
4
SGLT2 inhibitors vs. metformin for Parkinson's disease risk reduction in type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂与二甲双胍对2型糖尿病患者帕金森病风险的降低作用比较
J Parkinsons Dis. 2025 Jul 17:1877718X251359391. doi: 10.1177/1877718X251359391.
5
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和醛固酮拮抗剂联合肾素-血管紧张素系统拮抗剂对 2 型糖尿病合并慢性肾脏病患者主要肾脏不良结局的影响：系统评价和网络荟萃分析。
Diabetes Obes Metab. 2022 Nov;24(11):2159-2168. doi: 10.1111/dom.14801. Epub 2022 Jul 15.
6
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂对 2 型糖尿病成人患者心血管事件、死亡和主要安全性结局的影响：系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2016 May;4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8. Epub 2016 Mar 18.
7
Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes.在全国2型糖尿病患者群体中，GLP-1受体激动剂和SGLT2抑制剂使用者的治疗中断情况。
Diabetologia. 2025 May 2. doi: 10.1007/s00125-025-06439-x.
8
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.美国医疗体系中钠-葡萄糖共转运蛋白 2 抑制剂的处方模式。
J Am Coll Cardiol. 2024 Aug 20;84(8):683-693. doi: 10.1016/j.jacc.2024.05.057.
9
Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者心血管保护中的作用：系统评价。
J Diabetes Res. 2024 May 11;2024:9985836. doi: 10.1155/2024/9985836. eCollection 2024.
10
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.胰高血糖素样肽-1受体激动剂与钠/葡萄糖协同转运蛋白2抑制剂在预防2型糖尿病合并慢性肾脏病患者慢性肾衰竭及死亡方面的比较疗效
Am J Kidney Dis. 2025 Apr 29. doi: 10.1053/j.ajkd.2025.03.016.
本文引用的文献
1
Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease.糖尿病合并动脉粥样硬化性心血管疾病患者中钠-葡萄糖共转运蛋白 2 抑制剂的处方模式及相关因素。
CMAJ Open. 2023 Jun 13;11(3):E494-E503. doi: 10.9778/cmajo.20220039. Print 2023 May-Jun.
2
National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.2015 年至 2020 年，心脏病专家和其他专业医生使用钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的全国趋势。
J Am Heart Assoc. 2022 May 3;11(9):e023811. doi: 10.1161/JAHA.121.023811. Epub 2022 Apr 27.
3
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.SGLT2 抑制剂和 GLP-1 受体激动剂的利用率及其在动脉粥样硬化性心血管疾病和 2 型糖尿病患者中的医疗机构间差异：来自退伍军人事务部的观察。
Diabetes Care. 2022 Feb 1;45(2):372-380. doi: 10.2337/dc21-1815.
4
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2021 ACC/AHA/SCAI 冠状动脉血运重建指南：执行摘要：美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2022 Jan 18;145(3):e4-e17. doi: 10.1161/CIR.0000000000001039. Epub 2021 Dec 9.
5
Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up.钠-葡萄糖协同转运蛋白2抑制剂（SGLT2-I）对接受冠状动脉旁路移植术（CABG）合并体外循环（MiECC）治疗的缺血性心脏病（IHD）患者的影响：炎症负荷及5年随访的临床结局
Front Pharmacol. 2021 Nov 15;12:777083. doi: 10.3389/fphar.2021.777083. eCollection 2021.
6
Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists.在初级保健中开具 SGLT2 抑制剂处方：全科医生和内分泌学家的定性研究。
Diabetes Res Clin Pract. 2021 Oct;180:109036. doi: 10.1016/j.diabres.2021.109036. Epub 2021 Sep 2.
7
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.达格列净与 2 型糖尿病患者的心血管结局
N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
8
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.2007-2017 年全球范围内 2 型糖尿病心血管疾病患病率的系统文献回顾。
Cardiovasc Diabetol. 2018 Jun 8;17(1):83. doi: 10.1186/s12933-018-0728-6.
9
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.恩格列净可降低冠状动脉旁路移植术后 2 型糖尿病患者的心血管事件、死亡率和肾脏事件：EMPA-REG OUTCOME®随机试验的亚组分析。
Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19.
10
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
Zotero 插件